CN111544456A - Probiotic formula and application thereof - Google Patents
Probiotic formula and application thereof Download PDFInfo
- Publication number
- CN111544456A CN111544456A CN202010399071.9A CN202010399071A CN111544456A CN 111544456 A CN111544456 A CN 111544456A CN 202010399071 A CN202010399071 A CN 202010399071A CN 111544456 A CN111544456 A CN 111544456A
- Authority
- CN
- China
- Prior art keywords
- probiotic
- influenza
- hundred million
- foot
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a probiotic formula and application thereof, wherein each 0.05 ml of the probiotic formula solution contains: bifidobacterium animalis Bb-12: 1.5-2.0 hundred million; lactobacillus acidophilus: 1.5-2.0 hundred million; lactobacillus rhamnosus: 1.5-2.0 hundred million. The probiotic combination can coexist in a symbiotic manner, can induce an organism to generate a non-specific antibody, and improves the resistance of the organism; and can induce organism to generate specific antibody to main pathogen of hand-foot-mouth disease and/or influenza, and reduce virus-related lung damage by regulating inflammation coagulation reaction, and has certain preventing and treating effect on hand-foot-mouth disease and/or influenza and/or novel coronavirus pneumonia.
Description
Technical Field
The invention relates to a probiotic formula, in particular to a probiotic formula applied to influenza and/or novel coronavirus pneumonia and/or hand-foot-and-mouth disease.
Background
Probiotics refer to active microorganisms that improve the balance of the intestinal micro-ecology of the host and have positive benefits on the host. The probiotics help the digestion and absorption of nutrients; production of important nutrients; resisting infection of bacteria and viruses, improving immunity, and eliminating harm of harmful bacteria to human body.
Since probiotics on the market only improve the body resistance to a certain extent in a non-specific way and cannot generate specific antibodies against main pathogens of hand-foot-and-mouth disease and/or influenza, the prevention and treatment of the diseases are not influenced obviously.
Disclosure of Invention
(1) Technical problem to be solved
The invention aims to overcome the defect that probiotics in the current market only nonspecifically improve the body resistance to a certain extent and cannot generate specific antibodies aiming at main pathogens of hand-foot-and-mouth disease and/or influenza, and the technical problem to be solved by the invention is to provide a probiotic formula with a function of preventing and treating hand-foot-and-mouth disease and/or influenza.
(2) Technical scheme
In order to solve the technical problem, the invention provides a probiotic formula, wherein each 0.05 ml of probiotic formula solution contains:
bifidobacterium animalis Bb-12: 1.5-2.0 hundred million;
lactobacillus acidophilus: 1.5-2.0 hundred million;
lactobacillus rhamnosus: 1.5-2.0 hundred million;
the invention also provides a probiotic formulation comprising per 0.05 ml of probiotic formulation solution:
the invention also provides a probiotic formula, wherein each 0.05 ml of the probiotic formula solution contains:
the invention also provides a probiotic formula, wherein each 0.05 ml of the probiotic formula solution contains:
the invention also provides a probiotic formula, wherein each 0.05 ml of the probiotic formula solution contains:
the probiotics of the invention are selected from 500-1000 probiotics in intestinal tract, the probiotics which are proved to be beneficial to human life and health are selected, the probiotics which are helpful for preventing and treating influenza or hand-foot-and-mouth disease are selected, and the selected probiotics can coexist symbiotically.
The indications of the probiotic formula of the invention are:
before the intestinal flora system of less than or equal to 3 years old is humanized;
after the intestinal flora is changed remarkably after the age of 65 years;
patients with chronic diarrhea;
those taking antibiotics for a long time;
eczema, allergies, and the like.
The probiotic composition for preventing and treating influenza is administered 1 drop per day (0.05 ml) 1-2 months before influenza season, and is administered continuously for 2-3 weeks.
The probiotic composition for preventing and treating hand-foot-and-mouth disease is taken 1-2 months before the season of hand-foot-and-mouth disease, 1 drop, namely 0.05 ml, is taken every day, and the probiotic composition is continuously taken for 3-5 weeks.
(3) Advantageous effects
The probiotic combination can coexist and symbiotic, induce organisms to improve nonspecific antibodies and improve the body resistance.
The induction body generates specific antibodies to main pathogens of hand-foot-and-mouth disease and/or influenza, reduces lung damage related to influenza virus by regulating inflammatory coagulation reaction, and has certain prevention and treatment effects on hand-foot-and-mouth disease and/or influenza and/or novel coronavirus pneumonia.
Detailed Description
It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention. However, many modifications may be made to the specific embodiments disclosed, and still obtain a like or similar result, without departing from the spirit and scope of the present invention.
Example 1
This example provides a probiotic formulation comprising per 0.05 ml of probiotic formulation solution:
bifidobacterium animalis Bb-12: 1.5-2.0 hundred million;
lactobacillus acidophilus: 1.5-2.0 hundred million;
lactobacillus rhamnosus: 1.5 to 2.0 hundred million.
Wherein, in one embodiment, the amount of bifidobacterium animalis Bb-12 per 0.05 ml of the probiotic formula solution can be 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million. The lactobacillus acidophilus may be present in an amount of 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million per 0.05 ml of probiotic formulation solution. The number of lactobacillus rhamnosus may be 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million per 0.05 ml of probiotic formulation solution.
The probiotic formula solution is prepared by adopting a conventional process, and comprises the following steps:
respectively culturing animal bifidobacterium Bb-12, lactobacillus acidophilus and lactobacillus rhamnosus to obtain culture solution of corresponding probiotic strains. Will 107Inoculating a specific bacterial culture medium with any one of the probiotic strains in the order of magnitude; culturing at 15-38 deg.C for 9-72 hr under anaerobic or aerobic condition to obtain culture solution of the probiotic strain.
Preparing probiotic formula solution. And preparing the culture solution of the bifidobacterium animalis Bb-12, the lactobacillus acidophilus and the lactobacillus rhamnosus into probiotic formula solution according to the formula requirements.
In this embodiment, bifidobacterium Bb-12 and lactobacillus acidophilus are used as basic probiotics, which can activate innate immune system, improve natural killer cell activity, and mainly non-specifically improve body resistance to a certain extent. The reasons are that bifidobacterium animalis Bb-12 and lactobacillus acidophilus can stably reach the intestines through the high-acid and high-bile-salt environment of the intestines and the bifidobacterium animalis Bb-12 also contains bile-salt hydrolase, has strong adhesiveness, is more suitable for being used as a dietary supplement factor to normally breed in the intestinal tracts of human bodies to form dominant bacteria and fully exert the health promoting property of the dominant bacteria.
And, lactobacillus rhamnosus can increase mucosal secretory IgA levels, increase T lymphocyte and natural killer cell activities, cause significant increase of interleukin-12 levels in lung tissues, and significantly decrease interleukin-6, and tumor necrosis factor, thereby improving respiratory immunoreactivity, protecting host from influenza virus infection, and can also activate antiviral effects of inflammasome and human macrophages, and reduce influenza virus-associated lung damage by modulating inflammatory coagulation reactions.
The three strains are probiotics which normally coexist in intestinal tracts, can coexist in a symbiotic way, and are matched to induce organisms to improve nonspecific antibodies and improve the resistance of the organisms. Meanwhile, the antibody can induce organisms at a specific age stage to generate specific antibodies for main pathogens of influenza, particularly influenza A and influenza B, and can prevent and treat the influenza to a certain extent.
In this example, the probiotic formulation is indicated for the following conditions:
before the intestinal flora system of less than or equal to 3 years old is humanized;
after the intestinal flora is changed remarkably after the age of 65 years;
patients with chronic diarrhea;
those taking antibiotics for a long time;
eczema, allergies, and the like.
The strains in the probiotic formulation solutions of this example were produced by the DZG group of Australia and stored and provided by Lagrange health technology, Inc. The probiotic strains are directly prepared into a probiotic preparation for taking, the transportation and the storage of the finished product are the same as those of common probiotics, the constant temperature is below 25 ℃, no special requirement exists, the finished product can also be added into other products, and the products comprise food, medicines or health-care food and the like.
The probiotic formula solution obtained in the embodiment is used for researching 30 cases of influenza A children, and specifically comprises the following steps:
the probiotic formula solution is taken by 1 drop (0.05 ml) of each of 15 children patients every day, and is continuously taken until the children are cured, and the condition of the patient is observed. The other 15 children patients served as control group, each person did not take probiotic formula solution every day, and each person used 1 drop (0.05 ml) of distilled water every day until the disease healed, and the case condition was observed.
Preliminary research results show that after the probiotic formula solution is taken, the duration of fever, watery nasal discharge and cough of children patients tends to be shortened.
The probiotic formula solution can be applied to preventing and treating influenza and also can be applied to treating novel coronavirus pneumonia.
Probiotic prevention and treatment studies were performed on 58 patients with novel coronavirus pneumonia that had been confirmed by nucleic acid testing and chest radiography. As a result, after the probiotic combination is taken, the fever rate of the patients in the probiotic group (study group) is obviously reduced [ 34.8% (8/23) Vs 65.7% (23/35), X2 ═ 5.337, P ═ 0.021], the chances of fibrosis or infiltration or lung consolidation or pleural effusion of the lungs on the chest piece are obviously reduced [ 43.5% (10/23) Vs 71.4% (25/35), X2 ═ 4.531, P ═ 0.033], and the time for positive turning negative in nucleic acid detection is obviously shortened [11.30 ± 4.82dVs 15.06 ± 7.20d, t ═ 2.188, P ═ 0.033 ]. The probiotic formula solution plays a certain role in relieving inflammatory lung injury of novel coronavirus pneumonia and reducing infectivity of patients to a certain extent, and can be considered as one of effective auxiliary treatment means of coronavirus pneumonia.
Example 2
This example provides a probiotic formulation comprising per 0.05 ml of probiotic formulation solution:
wherein, in one embodiment, the amount of bifidobacterium animalis Bb-12 per 0.05 ml of the probiotic formula solution can be 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million. The lactobacillus acidophilus may be present in an amount of 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million per 0.05 ml of probiotic formulation solution. The number of lactobacillus rhamnosus may be 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million per 0.05 ml of probiotic formulation solution. The number of lactobacillus reuteri per 0.05 ml of probiotic formulation solution may be 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95 or 2.0 hundred million.
The probiotic formula solution is prepared by adopting a conventional process, and comprises the following steps:
respectively culturing animal bifidobacterium Bb-12, lactobacillus acidophilus, lactobacillus rhamnosus and lactobacillus reuteri to obtain culture solution of corresponding probiotic strains. Will 107Inoculating a specific bacterial culture medium with any one of the probiotic strains in the order of magnitude; culturing at 15-38 deg.C for 9-72 hr under anaerobic or aerobic condition to obtain culture solution of the probiotic strain.
Preparing a probiotic formula solution: and preparing the culture solution of the bifidobacterium animalis Bb-12, the lactobacillus acidophilus, the lactobacillus rhamnosus and the lactobacillus reuteri into probiotic formula solution according to the formula requirements.
In this embodiment, bifidobacterium Bb-12 and lactobacillus acidophilus are used as basic probiotics, which can activate innate immune system, improve natural killer cell activity, and mainly non-specifically improve body resistance to a certain extent. The reasons are that bifidobacterium animalis Bb-12 and lactobacillus acidophilus can stably reach the intestines through the high-acid and high-bile-salt environment of the intestines and the bifidobacterium animalis Bb-12 also contains bile-salt hydrolase, has strong adhesiveness, is more suitable for being used as a dietary supplement factor to normally breed in the intestinal tracts of human bodies to form dominant bacteria and fully exert the health promoting property of the dominant bacteria.
And, lactobacillus rhamnosus can increase mucosal secretory IgA levels, increase T lymphocyte and natural killer cell activities, cause significant increase of interleukin-12 levels in lung tissues, and significantly decrease interleukin-6, and tumor necrosis factor, thereby improving respiratory immunoreactivity, protecting host from influenza virus infection, and can also activate antiviral effects of inflammasome and human macrophages, and reduce influenza virus-associated lung damage by modulating inflammatory coagulation reactions.
And, lactobacillus reuteri has antiviral effects, and can protect skeletal muscle and colon cells from infection by coxsackie virus a and EV71 virus.
The four strains are probiotics which normally coexist in intestinal tracts and can coexist in a symbiotic way. The lactobacillus acidophilus and the lactobacillus reuteri can induce an organism to generate specific antibodies or inhibit the main pathogens from invading tissues and organs, and the lactobacillus rhamnosus and the lactobacillus reuteri can obviously relieve digestive tract symptoms of the hand-foot-and-mouth disease and have certain prevention and treatment effects on the hand-foot-and-mouth disease and the influenza.
In this example, the probiotic formulation is indicated for the following conditions:
before the intestinal flora system of less than or equal to 3 years old is humanized;
after the intestinal flora is changed remarkably after the age of 65 years;
patients with chronic diarrhea;
those taking antibiotics for a long time;
eczema, allergies, and the like.
The strains in the probiotic formulation solutions of this example were produced by the DZG group of Australia and stored and provided by Lagrange health technology, Inc. The probiotic strains are directly prepared into a probiotic preparation for taking, the transportation and the storage of the finished product are the same as those of common probiotics, the constant temperature is below 25 ℃, no special requirement exists, the finished product can also be added into other products, and the products comprise food, medicines or health-care food and the like.
The probiotic formula solution for preventing and treating influenza is taken 1-2 months before influenza season, 1 drop, namely 0.05 ml, is taken every day, and the administration is continued for 2-3 weeks.
The probiotic formula solution for preventing and treating the hand-foot-and-mouth disease is taken 1 drop by drop, namely 0.05 ml, 1-2 months before the season of the hand-foot-and-mouth disease, and is continuously taken for 3-5 weeks.
Example 3
This example provides a probiotic formulation comprising per 0.05 ml of probiotic formulation solution:
the formula is used for preventing and treating influenza (especially influenza A and influenza B) and hand-foot-and-mouth disease.
The probiotic formula solution obtained in the embodiment is used for researching 20 children suffering from hand-foot-and-mouth disease, and the method specifically comprises the following steps:
the probiotic formula solution is taken by 1 drop (0.05 ml) per day for 10 children patients, and is continuously taken until the children are cured, and the condition of the patient is observed. The other 10 infants served as control group, each person did not take probiotic formula solution every day, and each person used 1 drop (0.05 ml) of distilled water every day until the disease healed, and the case condition was observed.
The results show that after the probiotic formula solution is taken, the fever and the duration of the fever and the healing time of the rash of the children patients tend to be shortened.
Example 4
This example provides a probiotic formulation comprising per 0.05 ml of probiotic formulation solution:
the formula is used for preventing and treating influenza (especially influenza A and influenza B) and hand-foot-and-mouth disease.
Example 5
A probiotic formulation comprising per 0.05 ml of probiotic formulation solution:
the formula is used for preventing and treating influenza (especially influenza A and influenza B) and hand-foot-and-mouth disease.
The probiotics of the invention are selected from 500-1000 probiotics in intestinal tract, the probiotics which are proved to be beneficial to human life and health are selected, the probiotics which are helpful for preventing and treating influenza or hand-foot-and-mouth disease are selected, and the selected probiotics can coexist symbiotically.
The probiotic combination disclosed by the invention can coexist and symbiotically, and helps an organism to improve nonspecific antibodies and improve the body resistance. The induction organism generates specific antibodies to main pathogens of hand-foot-and-mouth disease and/or influenza, has certain prevention and treatment effects on the hand-foot-and-mouth disease and/or influenza, and has certain effects of relieving inflammatory lung injury and reducing infectivity of patients on novel coronavirus pneumonia.
The above examples are merely representative of preferred embodiments of the present invention, and the description thereof is more specific and detailed, but not to be construed as limiting the scope of the present invention. It should be noted that, for those skilled in the art, various changes, modifications and substitutions can be made without departing from the spirit of the present invention, and these are all within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (6)
1. A probiotic formulation characterized by comprising, per 0.05 ml of probiotic formulation solution:
bifidobacterium animalis Bb-12: 1.5-2.0 hundred million;
lactobacillus acidophilus: 1.5-2.0 hundred million;
lactobacillus rhamnosus: 1.5 to 2.0 hundred million.
2. The probiotic formulation according to claim 1, characterized in that per 0.05 ml of probiotic formulation solution it comprises:
3. the probiotic formulation according to claim 2, characterized in that per 0.05 ml of probiotic formulation solution it comprises:
4. the probiotic formulation according to claim 2, characterized in that per 0.05 ml of probiotic formulation solution it comprises:
5. the probiotic formulation according to claim 2, characterized in that per 0.05 ml of probiotic formulation solution it comprises:
6. use of a probiotic formulation according to any one of claims 1 to 5 for the prevention and treatment of influenza and/or novel coronavirus pneumonia and/or hand-foot-and-mouth disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910402511 | 2019-05-15 | ||
| CN2019104025119 | 2019-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111544456A true CN111544456A (en) | 2020-08-18 |
Family
ID=71999147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010399071.9A Pending CN111544456A (en) | 2019-05-15 | 2020-05-12 | Probiotic formula and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111544456A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402460A (en) * | 2020-12-14 | 2021-02-26 | 梁爱军 | Method for shortening cold course by using local probiotic liquid |
| WO2022180077A1 (en) * | 2021-02-24 | 2022-09-01 | Belano Medical Ag | Agent for binding and displacing corona viruses on living cells and on surfaces |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031313A (en) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| CN101336938A (en) * | 2007-07-02 | 2009-01-07 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
-
2020
- 2020-05-12 CN CN202010399071.9A patent/CN111544456A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031313A (en) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| CN101336938A (en) * | 2007-07-02 | 2009-01-07 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
Non-Patent Citations (3)
| Title |
|---|
| GAREAU MG等: "Probiotics and the gut microbiota in intestinal health and disease", 《NAT REV GASTROENTEROL HEPATOL》 * |
| 尹斐弘等: "儿童重症手足口病肠道菌群和肠道黏膜通透性的研究进展", 《中国微生态学杂志》 * |
| 邹杨等: "益生菌防治呼吸道感染的研究进展", 《中国当代医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402460A (en) * | 2020-12-14 | 2021-02-26 | 梁爱军 | Method for shortening cold course by using local probiotic liquid |
| WO2022180077A1 (en) * | 2021-02-24 | 2022-09-01 | Belano Medical Ag | Agent for binding and displacing corona viruses on living cells and on surfaces |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI592487B (en) | Novel lactobacillus paracasei subsp. paracasei k56 | |
| Wang et al. | Dietary fermented soybean meal replacement alleviates diarrhea in weaned piglets challenged with enterotoxigenic Escherichia coli K88 by modulating inflammatory cytokine levels and cecal microbiota composition | |
| Wang et al. | Assessment of probiotic properties of Lactobacillus salivarius isolated from chickens as feed additives | |
| TWI607758B (en) | Lactobacillus paracasei strain gmnl-653 and composition having the same for improving psoriasis symptoms | |
| CN110452842B (en) | Bifidobacterium lactis nbk-W13 and application thereof | |
| CN112940970B (en) | Intestinal probiotics and application thereof in treating tumors and replacing antibiotics | |
| CN111956671A (en) | Composite probiotics for treating helicobacter pylori infection | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| CN113913346B (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN113832077A (en) | Lactobacillus rhamnosus and application thereof | |
| CN111548972A (en) | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof | |
| CN114404458A (en) | Application of lactobacillus paracasei nbk-LC16 in improvement of helicobacter pylori infection and preparation of anti-inflammatory stomach-protecting product | |
| CN111544456A (en) | Probiotic formula and application thereof | |
| CN114390897A (en) | Composition of prebiotics and probiotics and application thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN110613738B (en) | Lactobacillus reuteri composition capable of relieving rheumatoid arthritis | |
| CN115820498A (en) | Lactobacillus plantarum YJ2406 and application thereof | |
| CN117883487B (en) | Composition for treating oral mucositis caused by radiotherapy and chemotherapy and preparation method thereof | |
| EP1587913B1 (en) | New strains of bifidobacterium having the ability to produce glutamine | |
| TWI598103B (en) | Composition of lactobacillus fermentum gmnl-296 and method for improving inflection symptoms of clostridium difficile | |
| CN117327632A (en) | Bifidobacterium animalis and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN115216434B (en) | Lactobacillus salivarius strain and application thereof | |
| CN111358813B (en) | Salt fog mixture for protecting respiratory tract | |
| ES2891536T3 (en) | Bifidobacterium animalis AMT30 strain and composition containing the Bifidobacterium animalis AMT30 strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |